Sulfonylureas in the Current Practice of Type 2 Diabetes Management: Are They All the Same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on Sulfonylureas Yousef Al-SalehShaun SabicoNasser M. Al-Daghri Guidelines Open access 13 May 2021 Pages: 2115 - 2132
Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs) Sanjay KalraSaptarshi BhattacharyaNitin Kapoor Review Open access 15 July 2021 Pages: 2133 - 2147
Differential Cost-Sharing Undermines Treatment Adherence to Combination Therapy: Evidence from Diabetes Treatment David R. NelsonPamela HeatonJieling Chen Original Research Open access 01 July 2021 Pages: 2149 - 2164
Comparative Effects of Metformin and Dipeptidyl Peptidase-4 Inhibitors in Japanese Obese Patients with Type 2 Diabetes: A Claims Database Study Masato OdawaraSumiko AoiKosuke Iwasaki Original Research Open access 04 July 2021 Pages: 2165 - 2177
Analysis Estimating the Potential Cost Impact of Utilizing Flash Glucose Monitoring with Optional Alarms in Swedish Adults with Diabetes with Impaired Awareness of Hypoglycaemia, Using Intensive Insulin Deirdre B. BlissettStig AttvallRichard A. Hellmund Original Research Open access 07 July 2021 Pages: 2179 - 2193
The Impact of Different Insulin-Related Measures on the Risk of Prediabetes Among the Chinese Han Population Huibiao QuanTuanyu FangZhiguang Zhou Original Research Open access 08 July 2021 Pages: 2195 - 2206
The Impact of COVID-19 Lockdown on Metabolic Control and Access to Healthcare in People with Diabetes: the CONFI-DIAB Cross-Sectional Study Lisa LudwigNicolas ScheyerBruno Guerci Original Research Open access 09 July 2021 Pages: 2207 - 2221
Risk Factors Associated with COVID-19 Hospitalization and Mortality: A Large Claims-Based Analysis Among People with Type 2 Diabetes Mellitus in the United States Kristina S. BoyeElif Tokar ErdemirLida Etemad Original Research Open access 18 July 2021 Pages: 2223 - 2239
Effect of Empagliflozin Versus Placebo on Plasma Volume Status in Patients with Acute Myocardial Infarction and Type 2 Diabetes Mellitus Yu HoshikaYoshiaki KubotaWataru Shimizu Brief Report Open access 08 July 2021 Pages: 2241 - 2248
SGLT2 Inhibitors and the Clinical Implications of Associated Weight Loss in Type 2 Diabetes: A Narrative Review Andrej JanežPaola Fioretto Brief Report Open access 09 July 2021 Pages: 2249 - 2261
Correction to: Cost Analysis of FreeStyle Libre® 2 System in Type 2 Diabetes Mellitus Population Itziar OyagüezFernando Gómez-PeraltaAntonio Pérez Correction Open access 09 July 2021 Pages: 2263 - 2264
Correction to: Sulfonylureas in the Current Practice of Type 2 Diabetes Management: Are They All the Same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on Sulfonylureas Yousef Al-SalehShaun SabicoNasser M. Al-Daghri Correction Open access 23 July 2021 Pages: 2265 - 2266